About Arcturus Therapeutics
Arcturus Therapeutics is a publicly listed company based in San Diego (United States) founded in 2013. RNAi technologies are developed for treating rare orphan diseases. It operates in the Healthcare and Technology sectors. Arcturus Therapeutics has raised $1.3 million across 7 funding rounds from investors including Cystic Fibrosis Foundation. The company has 176 employees. Its website arcturusrx.com draws about 13 thousand monthly visits. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Arcturus Therapeutics was founded in 2013 and is based in San Diego, United States. RNAi technologies are developed for addressing rare orphan diseases within the biotechnology sector. Proprietary LUNAR lipid-mediated delivery and STARR mRNA Technology are applied to create RNA medicines targeting rare and infectious diseases. The lead candidate, LUNAR-OTC, is directed toward ornithine transcarbamylase deficiency.
- Headquarters San Diego, United States
- Employees 176
- Stage Public
- SectorsHealthcareTechnology
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website arcturusrx.com
- Social LinkedIn X YouTube
- Legal Name Arcturus Therapeutics Holdings Inc.
- Annual Revenue$67.22 M (USD)-51.43as on Dec 31, 2025
- Net Profit-$65.78 M (USD)18.73as on Dec 31, 2025
- EBITDA-$71.93 M (USD)-102.15as on Dec 31, 2025
- Total Equity Funding$1.3M (USD)
in 7 rounds
- Investors
- Employee Count176
Apps and channels of Arcturus Therapeutics
its YouTube channel Arcturus Therapeutics has 589 subscribers and 30 videos.
Videos from Arcturus Therapeutics
The most watched videos on Arcturus Therapeutics's YouTube channel, Arcturus Therapeutics (589 subscribers). Click a video to play it here.
More on Arcturus Therapeutics.
Funding Insights of Arcturus Therapeutics
Arcturus Therapeutics has successfully raised a total of $1.3M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.3M
- Total Rounds 7
- First Round $1.3M
(Apr 2013)
- Investors Count 1
All 7 funding rounds of Arcturus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | Grant | – | – | ||
| Jan 2018 | $67.78M | Post-IPO | – | – | – |
| May 2017 | $3M | Grant | – | – | |
| Oct 2015 | $5.92M | Post-IPO | – | – | – |
| Dec 2013 | $5M | Post-IPO | – | – | – |
| Sep 2013 | $2.14M | Post-IPO | – | – | – |
| Apr 2013 | $1.3M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Arcturus Therapeutics
Arcturus Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cystic Fibrosis Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States |
Investor details for Arcturus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arcturus Therapeutics
104 people are tracked at Arcturus Therapeutics (49 in leadership, 13 in board & advisors, 42 in team); the tracked headcount is 176.
| Name | Role | Group |
|---|---|---|
Cindy Fisher | Vice President Of Regulatory Affairs | Leadership |
Igor Smolenov | Chief Development Officer (CDO) | Leadership |
Juergen Froehlich | Chief Medical Officer | Leadership |
Narae Lee | Associate Director | Leadership |
Constance Crowley | Executive Director/Senior Clinical Scientist | Leadership |
Ye Zhang | Chief Regulatory Officer | Leadership |
Alia Hawkes | Executive Director, Head of Pharmacovigilance | Leadership |
David Geller | VP Pulmonary and Rare Diseases | Leadership |
Natasha Bowman | Chief Human Resources Officer | Leadership |
Suezanne Parker | Senior Vice President Translational Biology | Leadership |
Rohit Mahajan | Vice President | Leadership |
Charles Cabral | Sr. Director MSAT | Leadership |
Lance Kurata | Chief Legal Officer | Leadership |
Joseph E. Payne | President & CEO | Leadership |
Yuling Wu | Senior Director | Leadership |
Daiki Matsuda | Executive Director, RNA Innovation | Leadership |
Mukunda Krishna, CPIM | Director - DS External Manufacturing Tech Ops And Supply | Leadership |
Mary Tan | V. President, Head of Global Technical, Ops & Supply | Leadership |
Jennifer Potter | Executive Assistant To President & Ceo, Cso, CFO & Vp, Ir/pr/m | Leadership |
Stefen Boehme | Director, Head of Drug Discovery | Leadership |
84 more people are available in the full profile.
Complete people profiles for Arcturus Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Arcturus Therapeutics
Arcturus Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ARCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Jun 2013
- Listed onNASDAQ: ARCT
- Listed entityArcturus Therapeutics Holdings Inc.
- Exchange sectorHealth technology
- ISINUS03969T1097
- Share price$12.03 (-4.6% on the day) · 2026-10-13
- Market capitalisation$341.9M
- EPS (diluted, trailing year)$-3.31
- Volume (last session)464,153
Financials of Arcturus Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $67.2M | -$65.8M | -$71.9M |
| 2024 | $138.4M | -$80.9M | -$35.6M |
| 2023 | $157.8M | -$29.7M | -$1.2M |
| 2022 | $206.0M | $9.3M | $18.9M |
| 2021 | $12.4M | -$203.7M | -$196.6M |
Detailed financial statements for Arcturus Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Arcturus Therapeutics
4 dated milestones of Arcturus Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Arcturus Therapeutics is founded.
- Funding First funding round of $1.3M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant,.
Competitors of Arcturus Therapeutics
Arcturus Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Arcturus Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arcturus Therapeutics
The website of Arcturus Therapeutics (arcturusrx.com) receives about 13K visits a month and ranks #1,709,034 among all websites worldwide, #2,313 in Biotechnology and Pharmaceuticals.
- Monthly visits13K
▼ 5.7% vs previous month
- Unique visitors5.9K
per month
- Global rank#1,709,034
among all websites
- Category rank#2,313
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit2.0
- Average visit34 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Arcturus Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fiercebiotech.com | 100% | 858.3K | #81,022 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Arcturus Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arcturus Therapeutics
Complete news archive for Arcturus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arcturus Therapeutics
Arcturus Therapeutics was founded in 2013.
Arcturus Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Arcturus Therapeutics is a funded company, having raised a total of $1.3M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.3M, raised on Apr 2013.
Arcturus Therapeutics has 176 employees.
Annual revenue of Arcturus Therapeutics is $67.22M as on Dec 31, 2025.
Arcturus Therapeutics was founded in 2013 and is based in San Diego, United States. RNAi technologies are developed for addressing rare orphan diseases within the biotechnology sector. Proprietary LUNAR lipid-mediated delivery and STARR mRNA Technology are applied to create RNA medicines targeting rare and infectious diseases. The lead candidate, LUNAR-OTC, is directed toward ornithine transcarbamylase deficiency.
Arcturus Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, Arcturus Therapeutics is publicly traded on NASDAQ under the ticker symbol ARCT.
Arcturus Therapeutics has 1 investor. Key investors include Cystic Fibrosis Foundation.